Pharmacokinetics and effectiveness of intravenous Levetiracetam administration for patients with status epilepticus

Pharmacokinetics and effectiveness of intravenous Levetiracetam administration for patients with status epilepticus - Pharmacokinetics of Levetiracetam

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028397

Enrollment

Registered

2017-07-27

Start date

2017-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Status epilepticus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who was eligible to another anticonvulsant drug even after benzodiazepine administration

Exclusion criteria

Exclusion criteria: Patients with contraindication to Levetiracetam administration. Patients with decreased renal function(under CCr:30ml/min). Patients who required haemodialysis or renal replacement therapy. Patients who had taken levetiracetam tablets previously on administration.

Design outcomes

Primary

Measure	Time frame
Maximum blood concentration just after the initial Levetiracetam administration and the minimum blood level at 12 and 48 hours later	—

Secondary

Measure	Time frame
Seizure suppression during Levetiracetam administration. Electroencephalogram within 24 hours after initial Levetiracetam administration, Biochemistry. Vital signs. Side effects.	—

Countries

Japan

Contacts

Public ContactKaneko Junya

Nippon Medical School Tama Nagayama Hospital Emergency and critical care center

kanekojunya0125@yahoo.co.jp042-371-2111

Outcome results